Valeant CEO: Allergan has a great set of assets

7:33 AM ET Wed, 23 April 2014

J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.